CA115-001 (Bristol Myers Squibb)
Description: Phase 1b/2 Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Participants with Advanced Solid Tumors and Non-small cell Lung Cancer
Target Patient Population: Starting with dose escalation in advanced solid tumors with specific cohorts in combination with Nivolumab
Study Design: Study Drug will be administered IV every 3 weeks.